JCR Pharmaceuticals Co Ltd banner
J

JCR Pharmaceuticals Co Ltd
TSE:4552

Watchlist Manager
JCR Pharmaceuticals Co Ltd
TSE:4552
Watchlist
Price: 597 JPY -3.08% Market Closed
Market Cap: ¥77.4B

Balance Sheet

Balance Sheet Decomposition
JCR Pharmaceuticals Co Ltd

Balance Sheet
JCR Pharmaceuticals Co Ltd

Rotate your device to view
Balance Sheet
Currency: JPY
Mar-2002 Mar-2003 Mar-2004 Mar-2005 Mar-2006 Mar-2007 Mar-2008 Mar-2009 Mar-2010 Mar-2011 Mar-2012 Mar-2013 Mar-2014 Mar-2015 Mar-2016 Mar-2017 Mar-2018 Mar-2019 Mar-2020 Mar-2021 Mar-2022 Mar-2023 Mar-2024 Mar-2025
Assets
Cash & Cash Equivalents
1 011
928
495
727
659
913
1 060
2 033
1 902
1 439
866
822
1 047
1 137
1 949
5 509
4 895
7 836
10 973
26 260
30 733
13 278
18 756
13 196
Cash Equivalents
1 011
928
495
727
659
913
1 060
2 033
1 902
1 439
866
822
1 047
1 137
1 949
5 509
4 895
7 836
10 973
26 260
30 733
13 278
18 756
13 196
Short-Term Investments
2 475
1 882
1 658
2 619
2 468
5 126
5 926
5 368
5 033
2 980
3 201
3 870
6 197
3 736
1 927
300
1 217
661
220
0
244
0
0
0
Total Receivables
4 637
3 725
3 718
3 149
3 020
3 033
2 906
3 000
3 038
3 899
4 042
4 900
3 869
5 204
5 384
5 435
7 103
8 835
7 977
8 183
15 585
11 137
14 934
12 236
Accounts Receivables
4 477
3 488
3 307
3 149
3 020
3 033
2 906
3 000
3 038
3 899
4 042
4 900
3 869
5 204
5 384
5 435
7 103
8 835
7 977
8 183
15 585
11 137
14 934
12 236
Other Receivables
160
237
411
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Inventory
6 987
6 678
6 125
4 606
3 954
3 667
3 339
3 215
4 097
4 575
5 110
4 990
5 105
6 402
7 343
7 738
9 023
9 117
8 855
13 554
14 636
18 514
20 933
21 758
Other Current Assets
333
425
486
1 497
1 549
509
1 374
619
880
928
1 024
1 404
1 154
712
1 763
1 333
593
919
317
548
990
4 873
2 958
3 866
Total Current Assets
15 443
13 638
12 482
12 599
11 650
13 248
14 605
14 235
14 951
13 821
14 243
15 986
17 373
17 191
18 366
20 315
22 831
27 368
28 342
48 545
62 188
47 802
57 581
51 056
PP&E Net
7 455
7 013
6 664
7 135
6 829
6 665
6 722
7 435
8 912
10 319
9 737
10 367
11 392
11 612
11 445
11 388
10 853
11 061
14 875
17 172
26 782
32 681
30 040
37 410
PP&E Gross
7 455
7 013
6 664
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Accumulated Depreciation
3 704
4 127
4 432
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Intangible Assets
15
16
20
22
17
20
19
59
119
121
99
79
95
75
84
68
112
110
263
3 232
2 960
3 652
3 496
2 960
Note Receivable
172
172
172
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Long-Term Investments
900
813
1 169
1 052
1 609
3 165
1 722
2 503
4 523
4 412
3 250
3 534
3 296
3 891
4 248
3 588
3 194
2 941
2 408
2 572
2 230
8 867
9 120
9 629
Other Long-Term Assets
1 604
1 399
1 723
991
694
1 304
1 151
535
644
1 145
1 638
1 322
1 309
1 317
1 204
1 027
1 408
1 036
1 887
2 263
2 974
1 935
1 989
3 800
Total Assets
25 588
N/A
23 051
-10%
22 229
-4%
21 799
-2%
20 799
-5%
24 403
+17%
24 219
-1%
24 767
+2%
29 148
+18%
29 817
+2%
28 967
-3%
31 287
+8%
33 464
+7%
34 086
+2%
35 347
+4%
36 385
+3%
38 398
+6%
42 516
+11%
47 775
+12%
73 784
+54%
97 134
+32%
94 937
-2%
102 226
+8%
104 855
+3%
Liabilities
Accounts Payable
1 109
980
824
383
332
345
438
809
915
955
229
736
697
534
783
700
585
586
679
2 932
1 324
1 563
890
590
Accrued Liabilities
253
265
244
170
183
200
210
236
300
309
331
393
433
465
558
599
640
743
790
913
1 004
1 088
1 130
1 216
Short-Term Debt
86
5
1
0
0
0
0
0
0
0
0
0
1 210
1 210
1 210
1 260
2 480
2 780
3 780
12 100
12 100
15 100
8 200
23 005
Current Portion of Long-Term Debt
3 464
2 299
3 161
2 910
2 404
2 283
1 877
1 893
1 994
2 025
2 239
2 278
891
948
775
464
606
1 028
1 146
768
3 071
2 243
796
3 100
Other Current Liabilities
597
385
302
502
472
1 215
1 538
1 555
2 153
1 544
1 622
2 219
2 432
1 978
2 741
1 684
2 794
3 547
4 039
12 315
24 555
15 768
19 119
16 077
Total Current Liabilities
5 509
3 933
4 532
3 964
3 391
4 043
4 063
4 494
5 362
4 833
4 421
5 626
5 664
5 135
6 067
4 707
7 105
8 684
10 434
29 028
42 054
35 762
30 135
43 988
Long-Term Debt
2 926
2 377
1 144
3 538
1 844
2 900
3 199
3 190
3 163
2 067
1 801
1 874
2 158
1 480
1 208
3 115
2 718
1 923
3 831
5 292
2 994
5 573
14 432
12 180
Deferred Income Tax
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Minority Interest
0
0
0
5
11
9
12
5
0
0
0
0
1
1
1
1
185
189
189
174
205
251
297
392
Other Liabilities
92
125
202
65
88
208
104
98
139
85
112
290
1 061
1 206
1 009
977
1 047
1 035
931
907
997
1 189
1 184
1 252
Total Liabilities
8 526
N/A
6 435
-25%
5 879
-9%
7 572
+29%
5 334
-30%
7 161
+34%
7 378
+3%
7 787
+6%
8 665
+11%
6 986
-19%
6 335
-9%
7 791
+23%
8 884
+14%
7 822
-12%
8 285
+6%
8 800
+6%
11 055
+26%
11 831
+7%
15 385
+30%
35 401
+130%
46 250
+31%
42 775
-8%
46 048
+8%
57 812
+26%
Equity
Common Stock
5 171
5 171
5 171
5 171
5 555
7 505
7 505
7 505
8 062
9 062
9 062
9 062
9 062
9 062
9 062
9 062
9 061
9 061
9 061
9 061
9 061
9 061
9 061
9 061
Retained Earnings
6 010
5 840
5 609
3 390
3 105
1 077
1 204
1 574
2 545
3 034
3 309
3 690
4 608
5 943
7 172
8 429
10 813
13 785
15 623
21 421
33 808
35 013
38 090
31 266
Additional Paid In Capital
5 937
5 937
5 937
5 939
6 461
8 411
8 411
8 411
9 779
10 780
10 780
10 788
10 933
10 950
10 961
10 965
10 947
10 922
10 891
10 941
10 994
10 384
10 384
10 392
Unrealized Security Profit/Loss
42
24
46
63
370
255
14
38
111
54
45
405
568
733
588
570
462
773
583
691
619
555
741
937
Treasury Stock
98
307
413
410
110
110
339
516
84
83
587
545
649
571
782
1 487
4 042
3 937
3 865
3 685
3 600
2 978
2 963
5 066
Other Equity
0
0
0
74
84
103
45
44
70
15
24
95
58
148
60
47
102
81
97
46
2
127
865
453
Total Equity
17 062
N/A
16 616
-3%
16 350
-2%
14 227
-13%
15 465
+9%
17 241
+11%
16 840
-2%
16 980
+1%
20 484
+21%
22 832
+11%
22 633
-1%
23 496
+4%
24 580
+5%
26 264
+7%
27 062
+3%
27 585
+2%
27 343
-1%
30 685
+12%
32 390
+6%
38 383
+19%
50 884
+33%
52 162
+3%
56 178
+8%
47 043
-16%
Total Liabilities & Equity
25 588
N/A
23 051
-10%
22 229
-4%
21 799
-2%
20 799
-5%
24 403
+17%
24 219
-1%
24 767
+2%
29 148
+18%
29 817
+2%
28 967
-3%
31 287
+8%
33 464
+7%
34 086
+2%
35 347
+4%
36 385
+3%
38 398
+6%
42 516
+11%
47 775
+12%
73 784
+54%
97 134
+32%
94 937
-2%
102 226
+8%
104 855
+3%
Shares Outstanding
Common Shares Outstanding
21
20
20
20
22
28
27
27
29
32
32
32
32
32
127
126
123
123
123
124
124
125
125
122
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett